In this study, we focused on patients with late-stage HR-positive/HER2-negative metastatic breast cancers who have received the 1st and 2nd line endocrine therapy previously, and used circulating tumor DNA to investigate the ET-resistant biomarkers and the therapeutic targets. This evidence concerns the gene ERBB2 and breast carcinoma.